GlassScriptPhysician profile
Lam Phung
NPI 1992231682
$4,437.86
in general payments reported to CMS, 2019-2025
15 companies · $424 in 2025
The $424 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,681 · 2023: $1,135 · 2024: $1,197 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,756.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,120.59 | 2022-2025 | Clareon, Rocklatan, Hydrus Microstent |
| Bausch & Lomb Americas INC. | $905.13 | 2022-2025 | Envista Mx60 Iol, Amvisc, Xiidra |
| Beaver-Visitec International, INC. | $447.78 | 2022 | |
| Sun Pharmaceutical Industries INC. | $376.79 | 2022-2025 | Cequa, Xelpros |
| Horizon Therapeutics Plc | $349.89 | 2022-2023 | Tepezza |
| Amgen INC. | $222.62 | 2024-2025 | Tepezza |
| Sight Sciences, INC. | $211.81 | 2022-2023 | Omni Surgical System, Tearcare System |
| Carl Zeiss Meditec USA, INC. | $190.36 | 2024 | Eq Workplace |
| Tarsus Pharmaceuticals, INC. | $110.31 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $106.05 | 2022 | |
| Oyster Point Pharma, INC. | $101.98 | 2023-2024 | Tyrvaya |
| Abbvie INC. | $97.04 | 2022-2024 | |
| Dompe US, INC. | $86.67 | 2023-2025 | Oxervate |
| Genentech USA, INC. | $78.33 | 2022 | |
| Harrow Eye, LLC | $32.51 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lam Phung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.